Gut Dysbiosis

The gut microbiome contains trillions of organisms that do far more than aid digestion. These bacteria, fungi, and viruses train the immune system, produce neurotransmitters like serotonin and GABA, maintain the intestinal barrier, and influence systemic inflammation. SARS-CoV-2 infects gut epithelial cells through the ACE2 receptor, and research has shown that viral RNA can persist in the gastrointestinal tract for months after acute infection. This persistent presence disrupts the microbial ecosystem in ways that may sustain Long COVID symptoms.

Studies comparing the gut microbiomes of Long COVID patients to healthy controls have found significant differences. Beneficial species like Faecalibacterium prausnitzii (a key producer of the anti-inflammatory short-chain fatty acid butyrate) are often depleted, while opportunistic and pro-inflammatory species are overrepresented. This imbalance, known as dysbiosis, compromises the intestinal barrier. When the gut lining becomes more permeable, bacterial fragments like lipopolysaccharide (LPS) can enter the bloodstream, triggering systemic immune activation. This gut-immune axis may help explain why Long COVID patients experience symptoms far beyond the digestive tract, including fatigue, brain fog, and joint pain.

Rebuilding the microbiome requires a layered approach. Targeted probiotics containing well-studied strains may help restore microbial diversity. Prebiotic fibers feed beneficial bacteria and support short-chain fatty acid production. Gut-barrier support nutrients like L-glutamine and zinc carnosine may help restore epithelial integrity. Dr. Groysman considers gut health assessment a standard part of his Long COVID evaluation, because microbiome disruption often underlies or amplifies symptoms in other organ systems.